FDA wants dementia-risk warning on HRT

02/11/2004 | Wall Street Journal, The

The FDA has decided pharmaceutical manufacturers should put additional information on the labels of their hormone replacement therapies, warning women that taking them could increase their risk of developing dementia or Alzheimer's disease. The hormone replacements have been linked previously with increased risk of breast cancer, heart attacks and strokes, but now the FDA wants new warnings, citing studies showing long-term users over 64 had a higher risk of dementia.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC